# OnCo record nct05732805 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05732805/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05732805", "NCT05732805" ;
  schema:name "A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma"@en ;
  schema:alternateName "OCTAVA"@en ;
  schema:description "A phase 3 trial testing BCD-217 in melanoma, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05732805/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05732805> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-08-02" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/bcd-217/>, <https://onco.cc/drugs/bcd-100/> ;
  onco:companies <https://onco.cc/companies/biocad/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05732805-eur-j-cancer-2025/> .